Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

02.11.2023 - First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023 ASH abstract to be ...

Related Keywords

United States ,Dana Farber Cancer Institute ,Massachusetts ,Watertown ,Boston ,American ,Sanofi Kymera ,Todd Cooper ,Nello Mainolfi ,Justine Koenigsberg ,Kymera Therapeutics Inc ,Exchange Commission ,American Society Of Hematology ,Nasdaq ,Drug Administration ,Development Expenses ,Program Background Information ,Boston Globe ,Company Sanofi ,Corporate Affairs ,International Conference On Molecular ,Immunology Rd Day ,Recent Developments ,American Society ,Fast Track ,Acute Myeloid Leukemia ,Molecular Targets ,Cancer Therapeutics ,Dana Farber Cancer ,Kymera Therapeutics ,Administrative Expenses ,Cash Equivalents ,Fierce Biotech ,Boston Business ,Binders Toolbox ,Private Securities Litigation Reform Act ,Kymera Therapeutic ,Annual Report ,Quarterly Report ,Vice President ,Kymera Therapeutics Chart ,Ymera Therapeutics Kurs ,Ymera Therapeutics Aktie ,